JP7653907B2 - ｐ５３ＷＴ腫瘍の処置の方法 - Google Patents

ｐ５３ＷＴ腫瘍の処置の方法 Download PDF

Info

Publication number
JP7653907B2
JP7653907B2 JP2021522967A JP2021522967A JP7653907B2 JP 7653907 B2 JP7653907 B2 JP 7653907B2 JP 2021522967 A JP2021522967 A JP 2021522967A JP 2021522967 A JP2021522967 A JP 2021522967A JP 7653907 B2 JP7653907 B2 JP 7653907B2
Authority
JP
Japan
Prior art keywords
lenalidomide
mdm4
mdm2
ck1α
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505884A (ja
Inventor
チェン，ジンウェイ
デカプリオ，ジェームス
パーク，ドンリム，エスター
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2022505884A publication Critical patent/JP2022505884A/ja
Priority to JP2024187067A priority Critical patent/JP2025026846A/ja
Application granted granted Critical
Publication of JP7653907B2 publication Critical patent/JP7653907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021522967A 2018-10-30 2019-10-28 ｐ５３ＷＴ腫瘍の処置の方法 Active JP7653907B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024187067A JP2025026846A (ja) 2018-10-30 2024-10-24 ｐ５３ＷＴ腫瘍の処置の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752382P 2018-10-30 2018-10-30
US62/752,382 2018-10-30
PCT/US2019/058319 WO2020092221A1 (en) 2018-10-30 2019-10-28 Method of treatment of p53 wt tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187067A Division JP2025026846A (ja) 2018-10-30 2024-10-24 ｐ５３ＷＴ腫瘍の処置の方法

Publications (2)

Publication Number Publication Date
JP2022505884A JP2022505884A (ja) 2022-01-14
JP7653907B2 true JP7653907B2 (ja) 2025-03-31

Family

ID=68582462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522967A Active JP7653907B2 (ja) 2018-10-30 2019-10-28 ｐ５３ＷＴ腫瘍の処置の方法
JP2024187067A Pending JP2025026846A (ja) 2018-10-30 2024-10-24 ｐ５３ＷＴ腫瘍の処置の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024187067A Pending JP2025026846A (ja) 2018-10-30 2024-10-24 ｐ５３ＷＴ腫瘍の処置の方法

Country Status (10)

Country Link
US (1) US12115151B2 (https=)
EP (1) EP3873460B1 (https=)
JP (2) JP7653907B2 (https=)
KR (1) KR102879859B1 (https=)
CN (1) CN112996503A (https=)
AU (1) AU2019369216B2 (https=)
CA (1) CA3115716A1 (https=)
ES (1) ES2986421T3 (https=)
IL (1) IL282485B2 (https=)
WO (1) WO2020092221A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN115216514B (zh) * 2022-08-01 2026-03-17 中国科学技术大学 Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388093B (es) * 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Hirose, M. et al.，MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation，Oncoscience，2014年，Vol.1, No.12，p.830-843，doi:10.18632/oncoscience.103
Houben, R. et al.，Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens，The Journal of Investigative Dermatology，2013年，Vol.133, No.10，p.2453-2460，doi:10.1038/jid.2013.169
Hu, B. et al.，MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin，The Journal of Biological Chemistry，2006年，Vol.281, No.44，p.33030-33035，doi:10.1074/jbc.C600147200
Liao, G. et al.，The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy，European Journal of Medicinal Chemistry，2018年09月18日，Vol.159，p.1-9，doi:10.1016/j.ejmech.2018.09.044
Manni, S. et al.，Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways，Oncotarget，2017年，Vol.8, No.9，p.14604-14619，doi:10.18632/oncotarget.14654

Also Published As

Publication number Publication date
US12115151B2 (en) 2024-10-15
WO2020092221A1 (en) 2020-05-07
IL282485B1 (en) 2025-05-01
US20210379039A1 (en) 2021-12-09
EP3873460A1 (en) 2021-09-08
AU2019369216A1 (en) 2021-05-20
JP2022505884A (ja) 2022-01-14
AU2019369216B2 (en) 2022-05-19
JP2025026846A (ja) 2025-02-26
KR20210087958A (ko) 2021-07-13
IL282485B2 (en) 2025-09-01
ES2986421T3 (es) 2024-11-11
EP3873460B1 (en) 2024-06-12
KR102879859B1 (ko) 2025-11-04
CN112996503A (zh) 2021-06-18
CA3115716A1 (en) 2020-05-07
IL282485A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
Dey et al. Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors
Li et al. NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3
JP2025026846A (ja) ｐ５３ＷＴ腫瘍の処置の方法
US20210251988A1 (en) Methods of treating disorders
WO2019246423A1 (en) Methods of treating disorders
JP2018531891A (ja) Ｂｅｔブロモドメインインヒビターに対する抵抗性の機構
Feng et al. CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A
Hu et al. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer
Morimoto et al. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF (V600E) mutant colorectal cancer
Gao et al. HB x protein‐mediated ATOH 1 downregulation suppresses ARID 2 expression and promotes hepatocellular carcinoma
CN115177728A (zh) Mapk/erk通路激活导致的癌症的治疗方法和应用及crept-cdk9复合物
Xing et al. Genome‐wide gain‐of‐function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma
US20250277215A1 (en) Long Non-Coding RNA 122 (Lnc122) for Treatment Cancer
Tokumoto et al. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth
HK40048199B (en) Method of treatment of p53 wt tumors
HK40048199A (en) Method of treatment of p53 wt tumors
Han et al. Translational regulation of SND1 governs endothelial homeostasis during stress
Popescu et al. Multi-selective RAS (ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
Brunet et al. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Hong The role of RB and its complex in CDK4/6 inhibitor therapy: Mechanisms of cell cycle regulation and oncolytic virus replication
EP4121171A1 (en) Pharmaceutical combination for the treatment of myeloproliferative neoplasms
JP2016529202A (ja) グリアジンペプチドを用いた癌の治療のためのキットおよび方法
Prince et al. Women in molecular and cellular oncology, volume II: 2022
D’Souza et al. Therapeutic Potential of Combining Receptor Tyrosine Kinase Inhibitor with Immune Checkpoint Blockade
RU2830814C2 (ru) Способ лечения рака поджелудочной железы

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250318

R150 Certificate of patent or registration of utility model

Ref document number: 7653907

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150